Unlocking the Potential of SH2 Domain‑Targeted Therapies
Recludix has developed a platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity.
Recludix is employing this platform approach first in the development of SH2 domain inhibitors that have favorable drug properties for the development of medicines against cancer and inflammatory diseases.
The platform is based on the integration of multiple technologies and expertise:
Recludix has created custom chemical libraries specifically tailored to targeting SH2 domains. The libraries are designed to be both drug-like, and to satisfy the unique features of SH2 binding sites.
Custom libraries are screened using proprietary approaches developed at Recludix that allow not only the identification of novel chemical matter, but rapid, massively parallel, early elucidation of structure activity relationships (SAR). Using Recludix’s experimental design, quantitative SAR information is obtained directly from primary screening results, providing a jump-start for further compound optimization by traditional medicinal chemistry and structure-based design.
Selectivity is a critical consideration in drug development. Recludix has developed a large and growing panel of SH2 domain assays to assess family-wide cross-reactivity of compounds. Every compound generated at Recludix during medicinal chemistry campaigns is screened against this large panel, thereby revealing structure-selectivity relationships and assuring that Recludix’s programs yield inhibitors that are confirmed to be selective.
Crystallography and Structure-Based Design
Recludix has established proprietary high-resolution small molecule co-crystallography systems for SH2 domain family members. The enablement of structure-based drug design has resulted in a deep understanding of critical binding features that drive potency and selectivity.